share_log

Jinghua Pharmaceutical Group Co., Ltd. (SZSE:002349) Looks Interesting, And It's About To Pay A Dividend

Jinghua Pharmaceutical Group Co., Ltd. (SZSE:002349) Looks Interesting, And It's About To Pay A Dividend

精华制药(SZSE:002349)看起来很有趣,并且即将支付股息。
Simply Wall St ·  06/07 20:27

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Jinghua Pharmaceutical Group Co., Ltd. (SZSE:002349) is about to go ex-dividend in just three days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. It is important to be aware of the ex-dividend date because any trade on the stock needs to have been settled on or before the record date. Accordingly, Jinghua Pharmaceutical Group investors that purchase the stock on or after the 12th of June will not receive the dividend, which will be paid on the 12th of June.

一些投资者依靠分红来增加财富,如果你是这些分红侦探中的一员,你可能会有兴趣知道精华制药集团股份有限公司(SZSE:002349)将于三天后进行除权。通常,除权日是股权记录日前的一个工作日,即公司确定有资格获得分红的股东的日期。了解除权日期非常重要,因为股票的任何交易都必须在股权记录日或之前结算。因此,6月12日之后购买精华制药集团股票的投资者将不会收到股息,该股息将于6月12日支付。

The company's next dividend payment will be CN¥0.092 per share, on the back of last year when the company paid a total of CN¥0.092 to shareholders. Last year's total dividend payments show that Jinghua Pharmaceutical Group has a trailing yield of 1.3% on the current share price of CN¥7.14. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to check whether the dividend payments are covered, and if earnings are growing.

该公司的下一个分红将为每股CN¥0.092,在去年,该公司总共支付给股东CN¥0.092。去年的总分红显示,精华制药集团目前的股价CN¥7.14的追溯收益率为1.3%。股息是许多股东的重要收入来源,但业务的健康状况对维持这些股息至关重要。因此,我们需要检查分红支付是否得到覆盖,收益是否在增长。

Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Fortunately Jinghua Pharmaceutical Group's payout ratio is modest, at just 32% of profit. That said, even highly profitable companies sometimes might not generate enough cash to pay the dividend, which is why we should always check if the dividend is covered by cash flow. Luckily it paid out just 23% of its free cash flow last year.

分红通常是用公司的收入支付的,所以如果公司支付的分红超过了其收入,那么其股息通常面临更高的风险。幸运的是,精华制药集团的支付比率很适中,仅占利润的32%。也就是说,即使是高盈利的公司有时也可能无法产生足够的现金来支付股息,这就是为什么我们应该始终检查股息是否有现金流来支付。幸运的是,去年它只支付了自由现金流的23%。

It's positive to see that Jinghua Pharmaceutical Group's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut.

看到精华制药集团的股息既由利润又由现金流支付,这是个积极的信号,因为这通常是一个分红可持续的迹象,而较低的支付比率通常意味着在股息被削减之前有更大的安全余地。

Click here to see how much of its profit Jinghua Pharmaceutical Group paid out over the last 12 months.

点击此处查看精华制药集团在过去12个月里支付的利润总额。

historic-dividend
SZSE:002349 Historic Dividend June 8th 2024
SZSE:002349历史分红2024年6月8日

Have Earnings And Dividends Been Growing?

收益和股息一直在增长吗?

Stocks with flat earnings can still be attractive dividend payers, but it is important to be more conservative with your approach and demand a greater margin for safety when it comes to dividend sustainability. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. With that in mind, we're not enthused to see that Jinghua Pharmaceutical Group's earnings per share have remained effectively flat over the past five years. Better than seeing them fall off a cliff, for sure, but the best dividend stocks grow their earnings meaningfully over the long run. Earnings per share growth in recent times has not been a standout. However, companies that see their growth slow can often choose to pay out a greater percentage of earnings to shareholders, which could see the dividend continue to rise.

即使业绩持平,股票仍可以成为有吸引力的股息赠送者,但是在红利可持续性方面,更加保守的做法更为重要,在企业进入低迷时期并削减股息的情况下,公司可能会大幅贬值。因此,我们并不太赞成看到精华制药集团的每股收益在过去五年里基本保持不变。当然,比起滑坡,这还是不错的,但最好的股息股票在长期内可以显着增长其盈利。近年来,每股收益的增长并不突出。然而,看到增长放缓的公司通常会选择向股东支付更高比例的盈利,这可能导致股息继续上升。

Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Jinghua Pharmaceutical Group has delivered an average of 19% per year annual increase in its dividend, based on the past 10 years of dividend payments.

衡量公司分红前景的另一个关键方法是通过衡量其历史分红增长率。基于过去10年的分红支付情况,精华制药集团的股息年均增长率为19%。

The Bottom Line

还有一件事需要注意的是,我们已经确定了上海医药的2个警告信号,了解这些信号应该成为你的投资过程的一部分。

Is Jinghua Pharmaceutical Group an attractive dividend stock, or better left on the shelf? The company has barely grown earnings per share over this time, but at least it's paying out a decently low percentage of its earnings and cashflow as dividends. This could suggest management is reinvesting in future growth opportunities. We would prefer to see earnings growing faster, but the best dividend stocks over the long term typically combine strong earnings per share growth with a low payout ratio, and Jinghua Pharmaceutical Group is halfway there. It's a promising combination that should mark this company worthy of closer attention.

精华制药集团是一只有吸引力的分红股票,还是最好放在一边的股票?该公司的每股收益仅略有增长,但至少它将其收益和现金流的支付比率保持在较低的水平,这可能表明管理层正在重投未来的增长机会。我们更希望看到盈利增长更快,但长期来看最好的股息股票通常将强劲的每股收益增长与低支付比率相结合,而精华制药集团已经达成了一半。这是一个有前途的组合,应该引起更多的关注。

While it's tempting to invest in Jinghua Pharmaceutical Group for the dividends alone, you should always be mindful of the risks involved. Our analysis shows 1 warning sign for Jinghua Pharmaceutical Group and you should be aware of this before buying any shares.

虽然仅仅为了领取分红而投资于精华制药集团很诱人,但你应该时刻谨记其中包含的风险。我们的分析显示精华制药集团存在1项警告,购买任何股票前你应该意识到这一点。

If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.

如果你在寻找强劲的股息支付者,我们建议查看我们的顶级股息股票选择。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发